Table 1. Baseline characteristics.
Characteristic | All patients | Colonized | Noncolonized | p Value |
---|---|---|---|---|
Number of patients (n, %) | 220 (100) | 90 (40.9) | 130 (59.1) | |
Median age (median, range) | 60.5 (18–85) | 59 (18–85) | 61.5 (19–82) | ns |
Male sex (n, %) | 111 (50.5) | 52 (57.8) | 59 (45.4) | ns |
Favorable genetic group (n, %) | 44 (20.3) | 15 (17) | 29 (22.5) | ns |
Intermediate genetic group (n,%) | 135 (62.2) | 61 (70.5) | 74 (57.4) | ns |
Adverse genetic group (n,%) | 37 (17.0) | 11 (12.5) | 26 (20.1) | ns |
Peripheral blood blast count* (median, range) | 28 (0–98) | 31.5 (0–93) | 26 (0–98) | ns |
Bone marrow blast count* (median, range) | 60 (5–96) | 60 (5–95) | 60 (5–96) | ns |
Lactate dehydrogenase* (median, range) | 406.5 (128–4803) | 426 (128–3819) | 402 (150–4803) | ns |
Thrombocytes* (median, range) | 53 (5–590) | 49.5 (10–590) | 54.5 (5–548) | ns |
Leukocytes* (median, range) | 14.62 (0.38–340) | 14.12 (0.38–340) | 15.19 (0.78–311.82) | ns |
Hemoglobin* (median, range) | 9.1 (3.5–16.2) | 9.25 (4.3–16) | 8,85 (3.5–16.2) | ns |
C-reactive protein* (median, range) | 2.94 (0.02–34.03) | 3.28 (0.02–34.03) | 2.73 (0.02–29.87) | ns |
*at time of diagnosis. All p-values reported are two-sided. Statistical significance was defined as p≤0.05.